KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Divestments (2016 - 2025)

Historic Divestments for Gsk (GSK) over the last 17 years, with Q4 2025 value amounting to $1.3 million.

  • Gsk's Divestments rose 11036.25% to $1.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$35.9 million, marking a year-over-year decrease of 2233.16%. This contributed to the annual value of -$35.6 million for FY2025, which is 5474.74% down from last year.
  • As of Q4 2025, Gsk's Divestments stood at $1.3 million, which was up 11036.25% from $1.3 million recorded in Q3 2025.
  • Gsk's 5-year Divestments high stood at $80.1 million for Q2 2023, and its period low was -$37.4 million during Q2 2025.
  • For the 5-year period, Gsk's Divestments averaged around -$1.0 million, with its median value being -$5.6 million (2023).
  • Data for Gsk's Divestments shows a peak YoY increase of 61144.65% (in 2023) and a maximum YoY decrease of 64351.35% (in 2023) over the last 5 years.
  • Quarter analysis of 5 years shows Gsk's Divestments stood at -$25.6 million in 2021, then surged by 45.05% to -$14.1 million in 2022, then skyrocketed by 611.45% to $72.0 million in 2023, then tumbled by 117.83% to -$12.8 million in 2024, then soared by 110.36% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q4 2025, $1.3 million for Q3 2025, and -$37.4 million during Q2 2025.